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Abstract
Background: Enterotoxigenic Escherichia coli (ETEC) is a major diarrheal pathogen in developing countries, where it
accounts for millions of infections and hundreds of thousands of deaths annually. While vaccine development to prevent
diarrheal illness due to ETEC is feasible, extensive effort is needed to identify conserved antigenic targets. Pathogenic
Escherichia coli, including ETEC, use the autotransporter (AT) secretion mechanism to export virulence factors. AT proteins
are comprised of a highly conserved carboxy terminal outer membrane beta barrel and a surface-exposed amino terminal
passenger domain. Recent immunoproteomic studies suggesting that multiple autotransporter passenger domains are
recognized during ETEC infection prompted the present studies.
Methodology: Available ETEC genomes were examined to identify AT coding sequences present in pathogenic isolates, but
not in the commensal E. coli HS strain. Passenger domains of the corresponding autotransporters were cloned and
expressed as recombinant antigens, and the immune response to these proteins was then examined using convalescent
sera from patients and experimentally infected mice.
Principal Findings: Potential AT genes shared by ETEC strains, but absent in the E. coli commensal HS strain were identified.
Recombinant passenger domains derived from autotransporters, including Ag43 and an AT designated pAT, were
recognized by antibodies from mice following intestinal challenge with H10407, and both Ag43 and pAT were identified on
the surface of ETEC by flow cytometry. Likewise, convalescent sera from patients with ETEC diarrhea recognized Ag43 and
pAT, suggesting that these proteins are expressed during both experimental and naturally occurring ETEC infections and
that they are immunogenic. Vaccination of mice with recombinant passenger domains from either pAT or Ag43 afforded
protection against intestinal colonization with ETEC.
Conclusions: Passenger domains of conserved autotransporter proteins could contribute to protective immune responses
that develop following infection with ETEC, and these antigens consequently represent potential targets to explore in
vaccine development.
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Introduction
Enterotoxigenic Escherichia coli (ETEC) are a major cause of
diarrheal illness in developing countries where these organisms
cause hundreds of millions of infections and an estimated 300,000–
500,000 deaths in young children each year [1]. ETEC are
perennially by far the most common cause of traveler’s diarrhea
[2]. Disease caused by ETEC is highly endemic in regions plagued
by inadequate sanitation and a lack of clean drinking water, and
prevention of ETEC is a high priority [1,3]. ETEC are genetically
heterogeneous pathogens that share the ability to colonize the
small intestine where they deliver the cholera toxin-like heat-labile
toxin (LT) and/or small peptide heat-stable (ST) toxins that
ultimately result in diarrhea [4].
In the classic paradigm for ETEC pathogenesis, small intestinal
colonization requires plasmid-encoded colonization factors (CFs)
[4]. A variety of more than 25 antigenically distinct fimbrial, or
fibrillar CFs have been described to date [5,6]. These antigens,
along with LT, remain central to ETEC vaccine development [7].
However, CF antigens are not appreciably cross-protective, and
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Moreover, LT alone (or the homologous cholera toxin) do not
appear to afford complete sustained protection [10], while ST,
typically only 19 amino acids in its mature form, is not suitably
immunogenic.
These constraints, as well as a growing appreciation of the
complexity of ETEC pathogenesis [4,11], have prompted searches
for additional surface-expressed antigens. Use of classical genetic
approaches including TnphoA mutagenesis to find novel molecules
exposed on the surface of ETEC, recently led to the identification
of several putative virulence loci, including the etpBAC two-
partner secretion locus [12], responsible for secretion of the EtpA
adhesin molecule [13], and the autotransporter (AT) protein EatA
[14].
EatA and other AT proteins contain three essential domains: an
amino terminal signal peptide, the secreted ‘‘passenger’’ domain,
and a third carboxy-terminal beta barrel domain inserted into the
outer membrane [15]. The variable passenger portion of the
protein may be cleaved by surface proteases and freely secreted as
in the case of EatA, or remain attached to the transport domain.
The surface expression of AT passenger domains proteins make
them attractive targets for vaccine development, while only limited
portions of the beta regions are predicted to be exposed [16].
While a broadly protective ETEC vaccine remains outstanding,
one approach currently being explored is a protein subunit vaccine
based on multiple ETEC antigens. Present acellular pertussis
vaccines [17,18,19], subunit formulations containing a two-
partner secretion (TPS) exoprotein adhesin (filamentous hemag-
glutinin, FHA) [20,21], the pertactin autotransporter [22,23], and
pertussis toxoid offer a potential strategy that might be adopted to
guide ETEC vaccine development. Indeed, recent investigations of
EtpA [12,13,24,25], an ETEC TPS exoprotein adhesin, were
prompted by its similarity to FHA. Recent immunoproteomic
studies of ETEC H10407 independently identified EtpA as well as
several AT proteins including EatA, TibA and antigen 43
suggesting that these proteins are expressed during both
experimental infection in mice and in humans [26].
Interestingly, it appears clear that children repeatedly exposed
to ETEC infections are ultimately protected against subsequent
symptomatic infections [27]. However, the precise composition of
the protective antigens remains uncertain [4,28,29]. The present
studies were performed to examine the possible contribution of
conserved, chromosomally-encoded AT proteins to protective
ETEC immune responses, and to evaluate passenger domains of
these ATs as possible candidates for ETEC vaccine development.
Methods
Bacterial strains and plasmids
A complete list of strains and plasmids employed in these studies
is included in table 1. ETEC strains H10407 and E24377A were
originally provided by Marcia Wolf and Stephen Savarino,
respectively, from cGMP lots maintained at Walter Reed Army
Institute of Research.
In silico analyses
A number of parallel bioinformatics approaches were used to
identify candidate AT genes in recently sequenced ETEC strains.
Strains B7A and E24377A were searched for highly conserved
autotransporter domains using the Pfam database including the
autotransporter beta domain (http://pfam.sanger.ac.uk//family/
PF03797) and the pertactin domain (http://pfam.sanger.ac.uk//
family/PF03212). The resulting sequences containing these
domains were used to identify additional autotransporters in the
genome of ETEC strain H10407 available in un-annotated form
via the Sanger Institute (http://www.sanger.ac.uk/Projects/E_coli_
H10407/), which was facilitated by interrogating the available
sequenceusing theNational Microbial PathogenDatabaseResource
(NMPDR) [30] on the Rapid Annotation Subsystem Technology
(RAST) server (http://RAST.nmpdr.org/) [31]. SignalP (http://
www.cbs.dtu.dk/services/SignalP/) was used to identify potential
signal peptide encoding regions of the predicted AT coding
sequences. BLASTP (http://blast.ncbi.nlm.nih.gov/Blast.cgi) and
Pfam domain searches of each putative AT peptide were used to
define the conserved beta barrel transport domain (TIGR01414,
and pfam03797, in the NCBI Conserved Domain Database http://
www.ncbi.nlm.nih.gov/Structure/cdd/cdd.shtml and Pfam data-
bases, respectively). Peptide sequence alignments of AT proteins
common to the three ETEC strains used ClustalW [32] and
MUSCLE [33] alignment algorithms performed locally (Mac OS
10.5.8) with an additional alignment plug-in (v1.06) for CLC Main
Workbench software (v 5.5).
Molecular cloning of autotransporter passenger domains
Regions corresponding to the majority of each passenger
domain (region between the end of the putative signal peptide
encoding sequence and the beginning of the beta barrel domain)
were amplified using primers bearing attB flanking sequences by
high fidelity PCR (Platinum PCR SuperMix, Invitrogen). A
complete list of primers used in these studies is included in table 2.
Resulting amplicons were agarose gel-purified (Ultra Clean 15,
MOBIO). Amplicons containing attB flanking sequences were
cloned by recombination with the lambda attP sites on the entry
vector pDONR221 (BP Clonase II, Invitrogen), and transformed
into DH10B One Shot ccdB Survival T1 Chemically Competent E.
coli (Invitrogen). Colonies were selected and patched onto
kanamycin and chloramphenicol plates. Plasmid DNA extracted
from kanamycin-resistant, chloramphenicol-sensitive colonies was
analyzed by restriction digest to confirm presence of the
Author Summary
Diarrheal diseases are responsible for more than 1.5 million
deaths annually in developing countries. Enterotoxigenic E.
coli (ETEC) are among the most common bacterial causes
of diarrhea, accounting for an estimated 300,000–500,000
deaths each year, mostly in young children. There
unfortunately is not yet a vaccine that can offer sustained,
broad-based protection against ETEC. While most vaccine
development effort has focused on plasmid-encoded
finger-like ETEC adhesin structures known as colonization
factors, additional effort is needed to identify conserved
target antigens. Epidemiologic studies suggest that
immune responses to uncharacterized, chromosomally
encoded antigens could contribute to protection resulting
from repeated infections. Earlier studies of immune
responses to ETEC infection had identified a class of
surface-expressed molecules known as autotransporters
(AT). Therefore, available ETEC genome sequences were
examined to identify conserved ETEC autotransporters not
shared by the commensal E. coli HS strain, followed by
studies of the immune response to these antigens, and
tests of their utility as vaccine components. Two chromo-
somally encoded ATs, identified in ETEC, but not in HS,
were found to be immunogenic and protective in an
animal model, suggesting that conserved AT molecules
contribute to protective immune responses that follow
natural ETEC infection and offering new potential targets
for vaccines.
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bined with pDEST17 (LR Clonase II) placing the passenger
domains in-frame with an amino-terminal polyhistidine tag in the
resulting expression plasmid. Cloning reactions were used to
transform DH5a to ampicillin resistance. Plasmid DNA from
ampicillin-resistant, chloramphenicol-sensitive colonies was ana-
lyzed first by restriction endonuclease digestion, then sequenced
using T7 promoter primer 59-TAATACGACTCACTATAGG-39
to confirm that the 6His- and passenger encoding sequences were
in-frame. Resulting plasmids were then used to transform E. coli
expression strain BL21-A1.
Production of recombinant polyhistidine-tagged
passenger proteins
To produce recombinant polyhistine-tagged passenger proteins
cultures of BL21-A1 containing pDEST17-encoded 6His-passen-
ger clones were grown overnight at 37uC in Luria broth
containing ampicillin (100 mg/ml). After diluting 1:100 in
100 ml of fresh media, cultures were grown at 37uC, 225 rpm
for approximately 3 hours to an OD600 of approximately 0.6, then
induced by the addition of L-arabinose to a final concentration of
0.02%. After approximately 2 hours, cultures were centrifuged for
5 minutes (4uC, 10,0006g), and the resulting pellet saved and
frozen at 280uC for subsequent processing. Pellets were thawed
on ice, and resuspended in binding buffer containing 20 mM Tris,
8 M Urea, 500 mM NaCl, 5 mM imidazole, protease inhibitor
cocktail (16, Sigma P8465) and PMSF (1 mM), at pH 8.0. After
lysis on a rotator for 30 minutes, the suspension was centrifuged
for 10 minutes at 10,0006ga t4 u C. Recombinant polyhistidine-
tagged autotransporter proteins (rATp) were then purified from
clarified lysates using immobilized metal affinity chromatography
(IMAC) in small-scale (His SpinTrap columns (GE Healthcare) or
Table 1. Bacterial strains and plasmids.
strains
strain description source/reference(s):
enterotoxigenic E. coli strains
B7A ETEC strain
b. origin: Vietnam; serotype O148:H28; CS6; LT+/ST+; EtpA2 [69,70]
H10407 ETEC strain
a. origin: Bangladesh; serotype O78:H11;CFA/1;LT+/ST+;EtpA+ [71,72]
E24377A ETEC strain
b. origin: Egypt; serotype O139:H28;CFA/II (CS1/CS3);LT+/ST+; EtpA+ [73]
Jf876 DlacZYA::Km
R derivative of H10407 [40]
recombinant E. coli strains
DH5a F- Q80lacZDM15 D(lacZYA-argF) U169 recA1 endA1 hsdR17 (rk2,m k+) phoA supE44 l- thi-1 gyrA96 relA1 Invitrogen
BL21-A1 F- ompT hsdSB (rB-mB-) gal dcm araB::T7RNAP-tetA Invitrogen
ccdB survival F- mcrA D(mrr-hsdRMS-mcrBC) W80lacZDM15 DlacX74 recA1 araD139 D(ara-leu)7697 galU galK rpsL (StrR) endA1 nupG Invitrogen
plasmids
plasmid description
pDONR221 4762 bp attP1/attP2 sites flanking CmR and ccdB; KmR Invitrogen
pDEST17 6354 bp T7-6His-attR1-CmR-ccdB-attR2/AmpR Invitrogen
p6H.Ag43.1p nt181-2013 of Ag43 in-frame with pDEST17 6His coding sequence present study
p6H.pATp nt334-1956 of pAT in-frame with pDEST17 6His coding sequence present study
genomic DNA sequence:
aWellcome Trust Sanger Institute, Cambridge, UK;
bjcvi (J. Craig Venter Institute).
CmR=chloramphenicol resistance; KmR=kanamycin resistance.
AmpR=ampicillin resistance.
ccdB=DNA gyrase toxin permits negative selection or plasmids which have not undergone in vitro recombination.
6His=polyhistidine tag.
nt:=nucleotides.
doi:10.1371/journal.pntd.0001428.t001
Table 2. Primers used for amplification of AT passenger domains.
gene
forward primer
59-ggggacaagtttgtacaaaaaagcaggctgg+
reverse primer
59-ggggaccactttgtacaagaaagctgggttta+
pAT …tatactaacgaaaccttc-39 …gccatgacgagagttggt-39
agn43.1 …gtggcgattgcgctgtct-39 …tacaccggtctgatggct-39
eatA …gcaacagttaatgcagatata-39 …ccgtaaatctcccatacg-39
Forward primers begin with sequence containing attB1 sites (underlined) and additional nucleotides (gg) to place following sequence in-frame with polyhistine coding
sequence in ultimate expression plasmid followed by gene-specific target sequences (…xxx-39).
Reverse primers begin with sequence containing attB2 sites (underlined) followed by stop codon (tta), then gene-specific target sequence.
doi:10.1371/journal.pntd.0001428.t002
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Healthcare). Proteins were eluted over an imidazole gradient
produced on a low-pressure chromatography system (BioLogic LP,
BioRad). Purity of recombinant proteins was assessed by SDS-
PAGE. Where necessary, fractions containing the protein of
interest were further purified by ion exchange (HiTrap Q) or by
SDS-PAGE and subsequent electroelution (Mini Whole Gel
Eluter, BioRad).
Antibody production and affinity purification
Polyclonal rabbit antisera were produced as previously
described (Rockland Immunochemicals, Gilbertsville, PA). Mouse
polyclonal antibodies were obtained upon sacrifice of mice follow-
ing completion of intranasal immunization with either adjuvant
control or adjuvant and recombinant protein of interest as
described below. Antibodies were affinity-purified as previously
described [13,34]. Briefly, antibodies were absorbed onto immo-
bilized antigen of interest on nitrocellulose, then eluted in 100 mM
glycine, pH 2.5 followed by neutralization with 1 M Tris, pH 8.0.
Immunoassays
To detect polyhistidine-tagged rATp proteins transferred onto
nitrocellulose, blocking was performed for one hour in 5% skim
milk in tris-buffered saline (pH 7.2) containing 0.05% Tween-20
(TBS-T), and subsequent immunoblotting used purified rabbit
polyclonal anti-His serum (1:500) and goat anti-rabbit immuno-
globulin G (Fc)-Horseradish peroxidase (HRP) (1:10,000). All wash
and incubation steps were performed in Tris-Buffered Saline
(pH 7.2)- 0.05% Tween 20. Detection used luminol-based
chemiluminescent substrate.
Assessment of immune responses to individual rATp proteins
was carried out in a similar fashion using pooled primary
convalescent sera (1:500) from mice following infection with
ETEC strain H10407. Pooled, pre-immune sera (1:500) from the
same mice was used as a primary antibody control. Sera obtained
from ETEC-infected children (ICDDR,B) Dhaka, Bangladesh,
and uninfected (age-matched) controls (LeBonheur Children’s
Medical Center, Memphis, TN), were tested at a 1:2048 dilution.
Primary antibody binding was detected using an HRP-labeled
secondary (anti-mouse or anti-human) antibody that detects IgA,
IgM and IgG (total Ab) and developed using sensitive chemilu-
minescent substrate (SuperSignal West Femto, Thermo Scientific).
Kinetic ELISA assays were performed as previously described
[24]. (For an in-depth discussion comparing kinetic and standard
end-point ELISA techniques, the reader is referred to an earlier
review available at http://www.biotek.com/resources/docs/Ki-
neticAppNoteFinal.pdf) [35]. ELISA wells were coated overnight
at 4uC with (100 ml/well) of individual rATp proteins diluted to a
final concentration of 4 mg/ml in 0.1 M NaHCO3 buffer (pH 8.6).
Plates were washed three times with TBS-T, blocked with TBS-T
containing 1% BSA (Blocker, Thermo Scientific) for 1 hour at
37uC. After washing briefly with TBS-T, plates were incubated
with dilutions of primary antibody in TBS-T/1% BSA for 1 hour
at 37uC, and again washed as above. Next, plates were incubated
(1 h, 37uC) with goat anti-human or goat anti-mouse secondary
antibody, which recognizes IgA, IgM, and IgG, at a final
concentration of 1:10000 in TBS-T-BSA. After washing, plates
were developed with TMB (3,39,5,59-Tetramethylbenzidine)
peroxidase substrate (Kirkgaard and Perry Laboratories). Kinetic
absorbance measurements [36] were determined at 650 nm,
acquired at 60 second intervals (Molecular Devices Spectramax
340PC microplate reader). SoftMax Pro v5.0.1 was used for data
recording and processing and the rate of substrate development
was expressed as the Vmax in milli-units/min.
Immunization of mice
Mice were vaccinated intranasally with candidate antigens as
previously described [37]. Briefly, groups of 10 ICR [38] mice
received either IVX908 (ProtollinH) [39] (7.5 mg) alone (con-
trols), or IVX908 (7.5 mg) + rATp domains (20 mg) on days 0, 14,
28. Sera were collected on day 0 prior to immunization (pre-
immune) and again 7–14 days after the final vaccination (post-
immune). Prior to bacterial challenge (day 42), 5–6 fresh fecal
pellets were collected from each mouse and immediately
suspended in 1.5 ml of extraction buffer containing Tris
(10 mM), NaCl (100 mM), Tween-20 (0.05%), and sodium azide
(5 mM) pH 7.4.
Intestinal colonization studies
Approximately 1 week after completion of the immunization
schedule, mice were challenged with jf876, a derivative of ETEC
H10407 containing a KmR marker in the lacZ gene as previously
described [37,40]. Two independent challenge studies were
completed; each involved a total of 30 mice including 10 controls
(IVX908 only), and groups of 10 mice vaccinated with either of the
two rATp proteins. Briefly, mice were treated with streptomycin
(5 g/liter) in their drinking water to eliminate colonization
resistance from competing normal enteric flora. Food was then
withheld 12 hours prior to ETEC challenge and sterile water was
used to replace the streptomycin solution. All mice received
cimetidine (50 mg/kg via intraperitoneal injection) 2 hours prior
to administration of bacteria. Mice were then challenged by
gavage administration of bacterial strain jf876 with total dose
between 10
4 and 10
5 cfu/mouse. Previous studies have demon-
strated that at 24 hours after inoculation with ETEC in the
murine model, the number of colonizing colony forming units in
the small intestine parallel values obtained at later time points
(72 hours) [38]. Therefore, in these studies, approximately
24 hours after challenge mice were sacrificed, samples of ileum
were harvested, then solubilized in saponin solution to release
bacteria, and finally plated onto Luria agar plates containing
kanamycin (25 mg/ml). Colonies were counted after incubation
overnight at 37uC. Intestinal lysates with no bacteria recovered
were assigned a value of 1 cfu (the lower limit of detection) as
previously described [37]. Care was taken to minimize the use of
animals in these experiments where possible. When necessary,
appropriate steps were taken to ameliorate suffering of mice
during vaccination and testing. The Institutional Animal Care and
Use Committees of the University of Tennessee Health Sciences
Center, and the VA Medical Center approved studies presented
here. All procedures involving mice complied with Public Health
Service guidelines, and The Guide for the Care and Use of
Laboratory Animals.
Flow cytometry
To evaluate surface expression of autotransporter passenger
domains, suspensions of H10407 in phosphate buffered saline
(PBS, pH 7.2) were first fixed with 2% paraformaldehyde for
15 minutes. After washing twice with PBS, cells were blocked with
1% BSA in PBS for 30 minutes. The resulting cell suspension was
incubated with either pre- or post-immune mouse sera (diluted
1:50 in blocking buffer) for 1 hour at room temperature (RT).
After washing three times with PBS, cells were incubated with
Alexa-Fluor (488)-labeled anti-mouse IgG [1:250] for 1 hour at
RT, washed three times, and resuspended in PBS. Analysis of cell-
bound fluorescence by flow cytometry used a BD FACSCalibur 4-
color, dual-laser flow cytometer equipped with a FACStation data
management system.
Conserved ETEC Autotransporter Passenger Vaccines
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Identification of additional ETEC autotransporter genes
In silico analysis of available ETEC genomes using searches for
one or more of the known highly conserved AT domains identified
multiple autotransporters in the genome of each ETEC strain.
From these, we selected AT genes that were present in ETEC, but
absent in the recently sequenced E. coli HS commensal isolate [41],
for additional study (table 3). All three genomes shared at least one
copy of both antigen43, and the pAT autotransporter genes
(figure 1). Similar to other pathovars [42], we identified two copies
of the agn43 gene in both H10407, and E24377A, but a single copy
in B7A.The aminoacid sequence ofthe passengerdomainsofthese
Ag43 molecules was highly conserved (supporting figure S1a), while
the pAT passenger domains exhibited approximately 70% identity
and 80% similarity (supporting figure S1b).
Although genes encoding proteins similar to pAT were found in
the Enterobacteriaceae by BLAST searches of the prototype pAT
molecule from H10407 (Uniprot designation E3PFJ1) in the
UniprotKB database, and were widely distributed among various
pathovars of E. coli as well as Salmonella, and Shigella species
(taxonomic distribution of these proteins is included in supporting
figure S2), only those in E. coli exhibited more than 80% identity.
As demonstrated in table 4, pAT homologues were identified in
other diarrheagenic E. coli pathotypes including enterohemor-
rhagic strains (EHEC), enteropathogenic isolates (EPEC), and
uropathogenic E. coli (UPEC), and extraintestinal pathogenic E.
coli (ExPEC) isolated from meningitis. However, we also identified
potential pAT homologues in non-HS commensal isolates from
humans [43] as well as animals [44], suggesting that while pAT
may not be essential for commensalism, it is not unique to
pathogenic strains.
Surface expression of autotransporter passenger
domains
Passenger domains of autotransporter proteins are exported to
the bacterial surface where they may be cleaved and appear in the
supernatant as in the case of EatA [14], or remain largely
associated with bacterial cell surface as has been described for
antigen 43 [42]. Antibodies raised against the recombinant
passenger domains of Ag43, pAT, and EatA were tested in kinetic
ELISA assays against the corresponding antigen as well as each of
the other rATp domains. These studies revealed little or no cross-
reactivity between antigens, suggesting that these proteins are
immunologically distinct (figure 2a). Flow cytometry detected
significant amounts of passenger domains of Ag43 and pAT
associated with the bacterial cell surface of ETEC H10407, but not
with the HS commensal strain (figure 2b). Likewise, pAT (figure 2c)
and Ag43 (figure 2d) were identified on the surface of both the
E24377A, and B7A ETEC strains.
Passenger domains of conserved chromosomally-
encoded autotransporter proteins are recognized during
infection
Because passenger domains of autotransporter proteins are
exported to the bacterial surface, they often elicit an immunologic
response in the host during the course of infection [45,46,47].
Furthermore, recent immuno-proteomic studies have indicated
that autotransporters are recognized during the course of
experimental infection in mice [26]. Therefore, we examined the
immune responses to conserved, chromosomally encoded auto-
transporter proteins identified in ETEC, using sera obtained from
mice following experimental infection and from humans following
natural ETEC infections.
Table 3. Comparison of selected autotransporter genes in ETEC and nonpathogenic E. coli strains.
Strain RAST* ncbi UniProt name length (AA)
identical
(%)
similar
(%) score
c
genes similar to antigen 43
H10407 2318 CBJ01621.1 E3PBK1 agn43.2
a 973 - - -
4884 CBJ03971.1 E3PD73 agn43.1
b 989 93 96 1762
E24377A 1041 YP_001464349.1 A7ZRC0 agn43.2
a 948 96 97 1817
2475 YP_001465820.1 A7ZVJ1 agn43.1
b 948 96 97 1815
B7A
{ 2219 ZP_03028954.1 B3HDS9 agn43 1039 74 79 1391
MG1655 2060 YP_026164.1 P39180 agn43 1039 71 76 1359
HS 2001 YP_001458811.1 A8A1M4 agn439 608 95 97 1042
genes similar to pAT
H10407 459 CBI99932.1 E3PFJ1 pAT 917 - - -
E24377A 2943 YP_001461547.1 A7ZIB8 pAT 922 82 87 1337
B7A 1772 ZP_03028580.1 B3HCJ6 pAT 962 75 83 1330
MG1655 379 AAB18097.1 na ‘pAT 465 98 99 908
HS 407 YP_001457207.1 A7ZX20 ‘pAT 465 93 97 810
*NMPDR RAST (Rapid Annotation using Subsystem Technology) at http://rast.nmpdr.org/.
{[B7A sequence is in draft form (198 contigs), therefore locations in B7A are inferred from surrounding genes].
aalternatively, also referred to as flu2 for ‘‘fluffing protein’’ 2.
balternatively, also referred to as flu1 for ‘‘fluffing protein’’ 1.
cby BLASTP algorithm http://blast.ncbi.nlm.nih.gov/Blast.cgi?CMD=Web&PAGE_TYPE=BlastHome.
na: not available.
‘denotes truncated pseudogene.
doi:10.1371/journal.pntd.0001428.t003
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tested H10407_Ag43, and H10407_pAT, demonstrated that the
passenger domain of both of these antigens is recognized during
the course of experimental intestinal infection in mice (figure 3 a).
This was also true of TibA and EatA passenger domains (not
shown) as predicted by earlier proteomic studies, however we
Table 4. pAT-like autotransporters in other E. coli pathovars and commensal E. coli strains
1,2.
accession
(UniProtKB) strain pathotype origin; clinical features length
identity
(%) reference
C8U260 12009 EHEC Isolated in Japan in 2001 from a patient with a sporadic case of bloody stool 992 89 [74]
E7HXI7 E128010 diarrheagenic Bangladesh, infant diarrhea 945 89 [75]
B3WPL7 B171 EPEC infant-toddler daycare diarrheal outbreak 992 89 [76]
B3I9D8 E22 EPEC weaned-rabbit diarrhea 992 89 [77]
D2ND18 SE15 commensal isolated from health adult, Japan 995 83 [43]
F5MCM6 AA86 commensal healthy cow feces 995 86 [44]
E1P987 ABU83972 - asymptomatic bacteriuria 995 83 [78]
B3HW28 F11 UPEC cystitis 995 83 [79]
Q1RFH4 UTI89 UPEC cystitis 995 83 [80]
D5CVR9 IHE3034 ExPEC meningitis 995 83 [81]
notes:
1recorded in the table are results obtained after BLASTP searches of the UniProt database with pAT from H10407, [http://www.uniprot.org/uniprot/E3PFJ1] using
following parameters: database was UniProtKB; threshold=0.0001; matrix=auto; low complexity regions filtered; gaps permitted.
2(the top ten BLAST hits with established disease association metadata are included).
doi:10.1371/journal.pntd.0001428.t004
Figure 1. Chromosomal context of conserved autotransporter genes in ETEC and nonpathogenic E. coli genomes.a .location of antigen
43 (agn43) genes in the chromosomes of ETEC strains (H10407, E24377A, and B7A) and nonpathogenic E. coli strains (MG1655, and HS). Genes are
shaded by similarity. Individual autotransporter genes are depicted in blue. Putative full-length autotransporter genes include their assigned ncbi
protein reference numbers. Mobility elements are depicted in green. Open arrows represent hypothetical genes. b. location of pAT genes (in blue).
Figures are based on RAST annotations (http://rast.nmpdr.org/).
doi:10.1371/journal.pntd.0001428.g001
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antigens, Ag43 and pAT. Subsequent studies demonstrated that
both Ag43 and pAT are recognized during the course of human
infections with ETEC (figure 3 b, c).
Immunization with passenger proteins protects against
ETEC colonization
To explore the utility of ETEC autotransporter proteins as
vaccine candidates, we examined both the immunogenicity and
protective efficacy of individual passenger domains for Ag43 and
pAT in a murine model of ETEC infection. For these studies, we
used the mucosal adjuvant Protollin (ivx908), a mixture of Shigella
flexneri 2a LPS, and meningococcal outer membrane proteins.
When delivered intranasally, Protollin (IVX908) elicits high levels
of S. flexneri LPS-specific fecal IgA [48], and when combined as
an adjuvant with other proteins, it promotes similarly robust
immune responses to target antigens [39,49]. Immunization with
either of the passenger domains for antigen 43 or pAT resulted in
significant increases in total serum and fecal antibody levels in
immunized mice relative to adjuvant-only (ivx908) controls
(figure 4a–c). Importantly, immunization with either rPATp or
rAg43p resulted in significant increases in fecal IgA directed at the
respective antigens (figure 4d).
Immunization with either the antigen43 or pAT recombinant
passenger domains provided significant protection against subse-
quent colonization with ETEC relative to adjuvant-immunized
controls (figure 4e).
Discussion
Despite the global importance of enterotoxigenic E. coli
infections, there is presently no vaccine against these pathogens
Figure 2. Surface expression of autotransporter proteins by ETEC. a. specificity of antibodies directed against ETEC autotransporter
passenger domains. Data shown are kinetic ELISA data obtained at a 1:1024 dilution of all primary antisera. b. flow cytometry study comparing the
presence of pAT and Ag43 AT passenger domains on the surface of ETEC strain H10407 compared to the HS E. coli commensal strain. Pre-immune (NI
for non-immune) sera, as well as unstained bacteria (no primary antibody) are shown as controls c. Examination of pAT surface expression by ETEC
strains B7A and E24377A relative to the H10407 (+ control) and the commensal HS (negative control); unstained control used no primary antibody. d.
Examination of Ag43 surface expression by ETEC strains B7A and E24377A relative to the H10407 and HS controls. Flow cytometry histograms depict
intensity of fluorescence signal on the abscissa (x-axis) while the relative frequency of bacteria counted is depicted on the ordinate (y-axis).
doi:10.1371/journal.pntd.0001428.g002
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development for ETEC is a challenge for a number of reasons.
First, the inherent plasticity of E. coli genomes makes discovery of
conserved, pathotype-specific antigens difficult [51,52]. In addi-
tion, much of the ETEC vaccine development effort to date has
focused on the plasmid-encoded colonization factors (CFs).
Unfortunately, antigenic heterogeneity and lack of appreciable
cross protection between CFs have been impediments to this
approach. To date, over twenty-five different CFs have been
identified in ETEC [53], and many strains do not appear to make
any of the known antigens [9,54]. Finally, carefully conducted
epidemiologic studies of natural ETEC infections have suggested
that LT and perhaps other as yet unidentified chromosomally-
encoded antigens [29], in addition to the plasmid-encoded CFs,
could be involved in protective immune responses.
Because we have recently demonstrated that several autotran-
sporter proteins are recognized following experimental and natural
ETEC infections [26], we chose to investigate the possible
contribution of conserved chromosomally-encoded autotranspor-
ter proteins. The studies here suggest that the passenger domains
of these autotransporters are recognized during the course of both
experimental infections in animals and naturally-occurring
infection in humans, and they validate recent immunoproteomic
data obtained with the prototype H10407 ETEC strain using sera
from infected mice or human convalescent sera [26].
Two additional autotransporters have previously been exam-
ined in ETEC pathogenesis. These include the chromosomally-
encoded TibA adhesin [55,56] protein and, EatA [14], a plasmid-
encoded member of the SPATE family (serine protease auto-
transporters of the Enterobacteriaceae). Both proteins are recognized
during the course of experimental and naturally occurring
infections [26]. Interestingly, the EatA protein appears modulate
adhesion and colonization by digesting another recently described
virulence molecule, the EtpA two-partner secretion exoprotein, an
adhesin [12,13]. In turn, this modulation of adherence appears to
be required for optimal delivery of heat-labile toxin (LT), a critical
ETEC virulence molecule [57]. Although recent data suggest that
both EtpA and EatA are reasonably conserved within the ETEC
pathovar [52,58,59], the inherent plasticity of E. coli genomes, and
the relative paucity of pathovar-specific virulence genes [51]
identified to date suggests that additional effort is warranted to
explore the potential utility of other highly conserved surface
structures as vaccine candidates.
Although it is likely that autotransporters contribute the overall
fitness of ETEC as a pathogen, neither of the proteins under study
here has been shown to contribute to the pathogenesis of ETEC.
Antigen 43 does however appear to be of importance in the
pathogenesis of other E. coli pathovars, including uropathogenic E.
coli (UPEC). In the urinary tract, Ag43 is expressed in intracellular
biofilm-like pods [60], and particular variants appear to contribute
to biofilm formation, and colonization of the urinary tract [61].
Similarly, immunoproteomic studies demonstrate that this antigen
is also expressed [62] and recognized [63] during the course of E
coli urinary tract infections in humans.
Interestingly, in a study of an E. coli laboratory isolate, Ag43
contributed to biofilm formation in vitro, but did not appear to play a
role in intestinal colonization in a murine model [64]. Nevertheless,
some studies have suggested that specific Ag43 alleles segregate with
diarrheagenic E. coli pathogens compared to other isolates from
other pathovars [65],and that ingeneral Ag43 was more commonly
found in pathogens than in commensal strains.
Assessing the precise contribution of given antigens to the
protective immune responses that develop following infection, or
even following vaccination can be challenging [66,67]. While
serologic responses to some CFs such as CFA/I have previously
been correlated with a protective immune response to ETEC [28],
it is likely that protection seen following natural infections reflects a
composite response to a number of antigens.
Figure 3. Immunogenicity of autotransporter protein passenger domains. a. passenger domains of autotransporters pAT and Ag43 are
recognized by during the course of experimental murine infection with ETEC H10407. Shown are metal affinity chromatography-purified antigens
(MAC) used in analysis, followed by corresponding immunoblots using pooled sera obtained from mice before and after intestinal challenge with
ETEC H10407. b. human ETEC convalescent sera (from patients infected with ETEC obtained at ICDDR,B), but not age-matched sera from uninfected
controls (from LeBonheur Children’s Hospital, Memphis) recognize the ETEC H10407 autotransporter passenger domain of pAT (RAST designation
459). c. human ETEC convalescent sera, but not age-matched control sera recognize passenger domain of the ETEC H10407 autotransporter Ag43
(RAST designation 2318).
doi:10.1371/journal.pntd.0001428.g003
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these antigens as well as other autotransporters in ETEC vaccines.
The surface expression of the autotransporter passenger domains,
their immunogenicity, and preliminary data presented here
support the concept that this class of molecules could serve as
protective antigens. Although the inherent plasticity of E. coli
genomes [68] in general poses an impediment to vaccine
development for ETEC, important data emerging from the
DNA sequencing of multiple ETEC genomes does suggest that
these pathogens maintain a core subset of relatively pathovar-
specific genes, such as the eatA autotransporter gene, that might
serve as suitable targets [52,59]. The suggestion that relatively few
genes separate the ETEC pathovar from commensal E. coli [58] is
an important consideration in moving forward with putative
ETEC vaccines. The data presented here suggest that other
autotransporters not unique to the ETEC pathovar contribute to
intestinal colonization, a critical step in ETEC pathogenesis as well
as the host immune response to these important pathogens.
Whether the more widely distributed ATs such as Ag43 and pAT
are truly dispensable for the commensal E. coli similar to the HS
prototype strain will be an important consideration in designing
both subunit and live-attenuated vaccine strategies.
Supporting Information
Figure S1 Conservation of antigen 43 and pAT passen-
ger domains. Shown are MUSCLE alignments for predicted
AT passenger regions selected from three sequenced ETEC
Figure 4. Vaccination with autotransporter passenger domains protects against intestinal colonization with ETEC in a murine
model. a. kinetic ELISA data showing serologic responses of animals vaccinated with passenger domain of autotransporter designated pATp (closed
circles) relative to adjuvant-only controls (ivx908, open circles). b. kinetic ELISA data for serologic responses of animals immunized with Ag43
passenger (Ag43p, closed triangles) relative to ivx908-only controls. c. kinetic ELISA of fecal antibodies (total IgG, IgM, IgA) obtained from pATp and
Ag43p immunized mice (closed symbols) relative to adjuvant-only controls (open symbols); antigen (in shaded region) on the x-axis refers to the
antigen used to coat ELISA wells. d. kinetic ELISA of fecal IgA antibody following vaccination with either the pAT or Ag43 passenger domains (closed
symbols) relative to adjuvant-only controls (ivx908, open symbols) e. KmR-bacteria recovered from intestinal lysates following challenge with
(1.2610
4 cfu/mouse) of jf876 (DlacZYA::KmR mutant of ETEC strain H10407). Dashed horizontal lines reflect geometric means. All statistical
comparisons were performed using two-tailed Mann Whitney analysis.
doi:10.1371/journal.pntd.0001428.g004
Conserved ETEC Autotransporter Passenger Vaccines
www.plosntds.org 9 December 2011 | Volume 5 | Issue 12 | e1428strains, (H10407, E24377A, and B7A): a. Ag43 autotransporters
H10407_Ag43.1, H10407_Ag43.2, E24377A_Ag43.1, and
E24377A_Ag43.2 and B7A_Ag43. (arrowhead shows predicted
signal peptide cleavage site) b. pAT from H10407, E24377A, and
B7A.
(PDF)
Figure S2 Distribution of potential pAT-like proteins in
the Enterobacteriaceae. The distribution of potential pAT-like
proteins was defined by BLASTP searches of Enterobacteriaceae
with pAT from H10407 [http://www.uniprot.org/uniprot/
E3PFJ1] using the UniProtKB database (threshold E value of
0.0001; filtered for low regions of complexity). The degree of
identity varied from 89% (for enterohemorrhagic E. coli strain
12009) to less than 50% for the other Enterobacteriaceae. Only E. coli
proteins were more than 80% identical to pAT. The closest
homologues in E. coli are shown in table 4.
(TIF)
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